27 related articles for article (PubMed ID: 38537599)
1. An experimental test of the nicotinic hypothesis of COVID-19.
Godellas NE; Cymes GD; Grosman C
Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2204242119. PubMed ID: 36279466
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Structure-Activity Relationships of Novel Peptide Derivatives of the Severe Acute Respiratory Syndrome-Coronavirus-2 Spike-Protein that Potently Inhibit Nicotinic Acetylcholine Receptors.
Hone AJ; Santiago U; Harvey PJ; Tekarli B; Gajewiak J; Craik DJ; Camacho CJ; McIntosh JM
J Med Chem; 2024 Jun; 67(11):9587-9598. PubMed ID: 38814877
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Binding of SARS-CoV-2 to ACE2 and Gangliosides in Native Lipid Membranes.
Dey M; Sharma A; Dhanawat G; Gupta D; Harshan KH; Parveen N
ACS Infect Dis; 2024 Mar; 10(3):907-916. PubMed ID: 38412250
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 spike ectodomain targets α7 nicotinic acetylcholine receptors.
O'Brien BCV; Weber L; Hueffer K; Weltzin MM
J Biol Chem; 2023 May; 299(5):104707. PubMed ID: 37061001
[TBL] [Abstract][Full Text] [Related]
5. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
6. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline.
Carlson EC; Macsai M; Bertrand S; Bertrand D; Nau J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982671
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19.
Lykhmus O; Kalashnyk O; Sullivan R; Skok M
J Neuroimmunol; 2023 Dec; 385():578244. PubMed ID: 38016403
[TBL] [Abstract][Full Text] [Related]
8. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
9. Agonists or positive allosteric modulators of α7 nicotinic acetylcholine receptor prevent interaction of SARS-Cov-2 receptor-binding domain with astrocytoma cells.
Kalashnyk O; Lykhmus O; Sullivan R; Komisarenko S; Skok M
Biochem Biophys Res Commun; 2024 May; 709():149825. PubMed ID: 38537599
[TBL] [Abstract][Full Text] [Related]
10. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
Borkotoky S; Dey D; Hazarika Z
Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
12. Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019.
Feng L; Fu S; Zhang P; Zhang Y; Zhao Y; Yao Y; Luo L; Ping P
Front Public Health; 2022; 10():1050034. PubMed ID: 36518573
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
